GWAS Services Market (2026-2036)

The growth of this market is mainly driven by the expansion of population-scale biobanks and national genomics programs, the increasing use of human genetic evidence to identify and validate drug targets, the growing development of polygenic risk scores for disease risk prediction, and the declining cost of genotyping and low-pass sequencing with imputation. In addition, the growing emphasis on genetic diversity in research cohorts, the integration of GWAS with electronic health records and multiomic data, the use of genomic selection in plant and animal breeding, and the adoption of cloud-based analysis and artificial intelligence (AI) are further supporting the growth of this market.

The Genome-Wide Association Study (GWAS) Services Market, also referred to as the genetic association study services market, genome-wide genotyping and analysis services market, or GWAS outsourcing market, comprises the services used to design, perform, and analyze studies that test genetic variants across the genome for association with diseases, traits, and drug responses. GWAS services include genotyping using high-density microarrays, low-pass whole-genome sequencing with imputation, and whole-genome and whole-exome sequencing; sample processing and quality control; genotype imputation using reference panels; statistical association testing; and post-GWAS analysis, including fine-mapping, functional annotation, polygenic risk score (PRS) development, Mendelian randomization, and the integration of genetic data with clinical and multiomic data. Services are delivered by genomics service laboratories, contract research organizations, bioinformatics companies, technology providers, and academic genotyping centers. The market ecosystem extends from genotyping and sequencing platform providers to service laboratories, biobanks and population health programs, pharmaceutical and biotechnology companies, academic research institutions, and agricultural breeding companies.

The market is experiencing steady growth as GWAS has become one of the most productive approaches in human genetics. By comparing the genomes of large numbers of people with and without a disease or trait, GWAS identifies genetic loci that influence disease risk, providing insights into disease biology and potential drug targets. Because GWAS power increases with sample size, the field has shifted toward very large studies involving hundreds of thousands to millions of participants, driving demand for high-throughput, low-cost genotyping and analysis. Drug targets supported by human genetic evidence are more likely to succeed in clinical development, encouraging pharmaceutical companies to invest in large genetic studies and partnerships with biobanks.

Population-scale biobanks and national programs are the most important source of demand. Our Future Health, the largest health research program in the U.K., has recruited more than 2 million consented participants and made genotype array data for 755,000 participants available to researchers, with imputed genotype data covering more than 159 million genetic variants first released in December 2025 and genetic ancestry data released in May 2026; Eurofins Genomics was selected to perform genotyping for up to 5 million participants in a dedicated U.K. laboratory. In June 2026, the All of Us Research Program of the U.S. National Institutes of Health (NIH) expanded its dataset to more than 747,000 participants, including 535,000 whole-genome sequences, nearly 482,000 linked electronic health records, and more than 1.3 billion genetic variants, with more than 86% of participants from communities historically underrepresented in health research. The U.S. Department of Veterans Affairs Million Veteran Program has enrolled more than one million veterans and has published a study of the genetic architecture of 2,068 traits across diverse ancestries. These programs create large, linked genetic and health datasets that are analyzed by academic and pharmaceutical researchers, generating demand for genotyping, imputation, and analysis services.

The technology used for GWAS is evolving. High-density genotyping arrays, such as the Illumina Infinium and Thermo Fisher Scientific Axiom biobank arrays, remain the most cost-effective method for genotyping very large cohorts, with Our Future Health genotype array data covering 686,416 variants imputed to more than 159 million variants. At the same time, the declining cost of sequencing is making low-pass whole-genome sequencing with imputation and full whole-genome sequencing increasingly competitive, as reflected in the 535,000 whole-genome sequences in the All of Us dataset. Sequencing-based approaches capture rare variants and structural variants that arrays miss, supporting more comprehensive association studies.

The scope of GWAS is also expanding beyond discovery. PRS developed from GWAS results are being evaluated for disease risk prediction and targeted screening, pharmacogenomic GWAS identify genetic factors that influence drug response and adverse events, and post-GWAS methods such as fine-mapping and Mendelian randomization help identify causal genes and evaluate drug targets. GWAS methods are also widely used in agriculture, where genomic selection and association studies support plant and animal breeding. In addition, the analysis of diverse populations is a growing priority, as most historical GWAS were performed in people of European ancestry, limiting the applicability of results to other populations.

The competitive landscape includes genotyping and sequencing technology providers, genomics service laboratories, and bioinformatics providers. Illumina and Thermo Fisher Scientific supply the leading genotyping array platforms, while service providers such as Eurofins Genomics, LGC Biosearch Technologies, Novogene, Azenta Life Sciences, and Macrogen offer genotyping and sequencing services. The ownership of large genetic datasets is also changing. In 2025, TTAM Research Institute, a nonprofit led by 23andMe co-founder Anne Wojcicki, received bankruptcy court approval to acquire substantially all assets of 23andMe, including its Personal Genome Service and Research Services businesses, for USD 305 million, topping an earlier USD 256 million proposal from Regeneron Pharmaceuticals.

At the same time, the market faces challenges related to data privacy and governance, funding constraints, and the complexity of analyzing very large datasets. NIH funding for the All of Us Research Program was about USD 158 million in fiscal year 2025, roughly 71% lower than in fiscal year 2023, illustrating the impact of public funding constraints on large genomics programs. As a result, service providers that can deliver low cost per sample, high data quality, secure data handling, and advanced analysis are expected to capture the largest share of growth over the forecast period.